Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy
Recruiting · NCT06667622 · Interventional (participants receive a specific treatment) · Lead sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
View the official record on ClinicalTrials.gov →Interventions studied
sodium glycididazole
What this trial is about
To evaluate the efficacy and toxicity of sodium glycididazole combined with concurrent chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer after neoadjuvant chemoradiotherapy.
Who can take part
Age range
18 Years to 70 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patients must have histologically or cytologically confirmed non-small cell lung cancer.
- Patients with unresectable stage II-III non-small cell lung cancer after neoadjuvant therapy.
- ECOG PS 0-2
- Adequate organ and bone marrow function.
Exclusion criteria
- History of previous radiotherapy.
- The previous immune-related pneumonitis ≥ grade 2.
- Local lesions require surgery.
- History of another primary malignancy.
- History of active primary immunodeficiency.
- Histological findings showed mixed small cell lung cancer and non-small cell lung cancer.
- For any unmitigated toxicity during pre-study chemoradiotherapy.
Where it is running
1 location listed.
- Cancer Hospital Chinese Academy of Medical Sciences - Beijing, Beijing Municipality, China